COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection

University Hospital, Ioannina50 enrolled

Overview

Effect of Covid-19 disease in clotting factors levels in hospitalized patients

Effect of Covid-19 disease in clotting factors levels in hospitalized patients positive for sars-cov2 infection. Association between clotting factors levels and disease severity,morbidity and mortality in these patients. Effect of anticoagulant therapy in the clotting factors' levels in these patients

Study Type

OBSERVATIONAL

Enrollment

Conditions

SARS-COV2 Infection COVID-19 Disease Hospitalized Patients

Interventions

low molecular weight Heparin as standard of care treatmentDRUG

STANDARD OF CARE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * AGE\> 18 * SINGED INFORMED CONSENT FORM * POSITIVE PCR TEST FOR SARS-COV2 INFECTION * FINDINGS IN CXR OR CT OF THE LUNGS CONSISTENT WITH INFECTION OF LOWER RESPIRATORY TRACT Exclusion Criteria: * AGE\<18 * DENIAL TO PROVIDE INFORMED CONSENT FORM * HISTORY OF MALIGNANCY * PRIOR USE OF ANTICOAGULANT THERAPY * PRIOR USE OF STEROIDS LONGER THAN 14 DAYS * LACTATION-PREGNANCY

Locations (1)

University General Hospital of Ioannina

Ioannina, Epirus, Greece

Outcomes

Primary Outcomes

EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS

leves of cloting factors before and after treatment with LMWH

Time frame: 6 MONTHS

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.